A $600M divestiture of the Life Sciences & Healthcare segment will sharpen focus on AI-driven intelligence for Academia & Government and Intellectual Property, with proceeds used to reduce debt. 2026 guidance is reaffirmed, projecting revenues of $2.30B–$2.42B and Adjusted EBITDA of $980M–$1.04B.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.